Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block
NCT04209504
Recruiting
This prospective observational study aims to evaluate the incidence of hemidiaphragmatic paralysis in patients receiving interscalene brachial plexus nerve block with prolonged neural blockade. English speaking American Society of Anesthesiologists (ASA) 1-3 patients ages 18-80 receiving prolonged interscalene nerve block will be randomized into 3 groups: first group receiving a perineural catheter infusing 0.2% ropivacaine; the second group receiving a single shot injection of 10mL liposomal bu... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/03/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Shoulder Surgery, Shoulder Pain, Shoulder Injuries, Shoulder Arthritis, Shoulder Disease, Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Arthropathy of Left Shoulder, Rotator Cuff Arthropathy of Right Shoulder, Rotator Cuff Repair
Register for Updates
Reaching for Equity in Sleep Apnea Treatment (REST) Study
NCT04209985
Recruiting
This study will test a brief telephonic health coaching intervention to improve adherence to positive airway pressure therapy for treatment of obstructive sleep apnea.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Zuckerberg San Francisco General Hospital Sleep Clinic, San Francisco, California
Conditions: Sleep Apnea
Register for Updates
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT04265872
Recruiting
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with bortezomib therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates
Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension
NCT04454203
Recruiting
The goal of this prospective randomized double-blind study is to determine if an ultrasound guided peri-arterial injection of local anesthetic (LA) superomedially the femoral artery via peripheral nerve catheter reverses ischemic hypertension associated with prolonged lower extremity tourniquet time.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Register for Updates
Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement
NCT04527445
Recruiting
Fluoroscopy is performed when placing a lead during a sacral neuromodulation procedure. During lead placement, subjects will receive either conventional or experimental fluoroscopic settings. The radiation exposure will be compared between the two groups.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
02/03/2025
Locations: Loma Linda University Health, Loma Linda, California
Conditions: Radiation Exposure, Overactive Bladder, Urge Incontinence, Urgency-frequency Syndrome
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: UAB Division of Hematology/Oncology, Birmingham, Alabama +148 locations
Conditions: Myelofibrosis
Register for Updates
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
NCT04583514
Recruiting
Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the... Read More
Gender:
ALL
Ages:
Between 18 years and 42 years
Trial Updated:
02/03/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Overweight and Obesity, Metabolic Syndrome
Register for Updates
Coping Together: Couple-based Interventions for Cancer
NCT04590885
Recruiting
The objective of the proposed study is to evaluate the Couple Communication Skills Training (CCST) intervention in 250 patients with advanced cancer and their spouses/intimate partners. Couples will be randomized 1:1 to receive either the CCST or to an attention control condition (Healthy Living Information; HLI). We will evaluate CCST effects on a range of patient and partner relationship and psychological outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Advanced Cancer
Register for Updates
Statins for the Treatment of NASH
NCT04679376
Recruiting
The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/03/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Studying How Outpatient Water AffEcts Risks with Drains (SHOWER Study)
NCT04725916
Recruiting
This is a prospective randomized, controlled, unblinded, interventional feasibility study to evaluate if showering with post operative drains in place leads to an increase in complications. The patients included in the study will be those undergoing breast reductions and panniculectomies at Geisinger Medical Center. The patients will be randomized post operatively into one of two groups: 1) patients instructed to shower with drains in place, and 2) patients instructed not to shower while they ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Geisinger Health, Danville, Pennsylvania
Conditions: Postoperative Wound Infection, Postoperative Complications, Surgical Site Infection, Drain Site Complication
Register for Updates
BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826
Recruiting
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: City of Hope National Medical Center, Duarte, California +18 locations
Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Register for Updates
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
NCT04852328
Recruiting
This is a phase 2 trial to assess the safety and tolerability of three schedules of CUE-101 administered in the neoadjuvant phase before standard of care (SOC) therapy to treatment naïve, HLA-A\*0201 positive patients with newly diagnosed, locally advanced HPV16+ oropharyngeal squamous-cell carcinoma (OPSCC). This is an exploratory trial of a limited sample size to confirm safety and to assess for pharmacodynamic signals of efficacy in each of three schedules of CUE-101. Safety assessments will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Oropharyngeal Squamous Cell Carcinoma
Register for Updates